← Back

Wire · opportunities

Ichnos Glenmark Files IND for ISB 2301 Cancer Drug

Published

22 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at wisevoter.com →

◆ Verified

Fusion42 · 22 November 2026 · Fusion42 review

Ichnos Glenmark Innovation has filed an Investigational New Drug application with the FDA for ISB 2301, a pentaspecific immune cell activator targeting solid tumours, with Phase 1 trials planned for 2027.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You should update your drug pipeline plans now that multi-target immune therapies are moving into solid tumour trials backed by regulatory progress. The outcome of the upcoming Phase 1 trial will define whether you can enter this competitive approach against immune-resistant cancers.

◆ Coverage

1 source · 22 Nov 2026

◆ Related on Wire

◆ Topics

Biotechcancer-drugimmotherapyfda-indclinical-trialssolid-tumours